Harnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global threat with an ever-increasing death toll even after a year on. Hence, the rapid identification of infected individuals with diagnostic tests continues to be crucial in t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kok Gan Chan, Geik Yong Ang, Choo Yee Yu, Chan Yean Yean
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	coronavirus COVID-19 isothermal amplification antiviral CRISPR-Dx Science Q
Acceso en línea:	https://doaj.org/article/9da121a38a37495891d9221b3fdf9b83
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9da121a38a37495891d9221b3fdf9b83
record_format	dspace
spelling	oai:doaj.org-article:9da121a38a37495891d9221b3fdf9b832021-11-25T18:11:14ZHarnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics10.3390/life111112102075-1729https://doaj.org/article/9da121a38a37495891d9221b3fdf9b832021-11-01T00:00:00Zhttps://www.mdpi.com/2075-1729/11/11/1210https://doaj.org/toc/2075-1729The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global threat with an ever-increasing death toll even after a year on. Hence, the rapid identification of infected individuals with diagnostic tests continues to be crucial in the on-going effort to combat the spread of COVID-19. Viral nucleic acid detection via real-time reverse transcription polymerase chain reaction (rRT-PCR) or sequencing is regarded as the gold standard for COVID-19 diagnosis, but these technically intricate molecular tests are limited to centralized laboratories due to the highly specialized instrument and skilled personnel requirements. Based on the current development in the field of diagnostics, the programmable clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) system appears to be a promising technology that can be further explored to create rapid, cost-effective, sensitive, and specific diagnostic tools for both laboratory and point-of-care (POC) testing. Other than diagnostics, the potential application of the CRISPR–Cas system as an antiviral agent has also been gaining attention. In this review, we highlight the recent advances in CRISPR–Cas-based nucleic acid detection strategies and the application of CRISPR–Cas as a potential antiviral agent in the context of COVID-19.Kok Gan ChanGeik Yong AngChoo Yee YuChan Yean YeanMDPI AGarticlecoronavirusCOVID-19isothermal amplificationantiviralCRISPR-DxScienceQENLife, Vol 11, Iss 1210, p 1210 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	coronavirus COVID-19 isothermal amplification antiviral CRISPR-Dx Science Q
spellingShingle	coronavirus COVID-19 isothermal amplification antiviral CRISPR-Dx Science Q Kok Gan Chan Geik Yong Ang Choo Yee Yu Chan Yean Yean Harnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics
description	The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global threat with an ever-increasing death toll even after a year on. Hence, the rapid identification of infected individuals with diagnostic tests continues to be crucial in the on-going effort to combat the spread of COVID-19. Viral nucleic acid detection via real-time reverse transcription polymerase chain reaction (rRT-PCR) or sequencing is regarded as the gold standard for COVID-19 diagnosis, but these technically intricate molecular tests are limited to centralized laboratories due to the highly specialized instrument and skilled personnel requirements. Based on the current development in the field of diagnostics, the programmable clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) system appears to be a promising technology that can be further explored to create rapid, cost-effective, sensitive, and specific diagnostic tools for both laboratory and point-of-care (POC) testing. Other than diagnostics, the potential application of the CRISPR–Cas system as an antiviral agent has also been gaining attention. In this review, we highlight the recent advances in CRISPR–Cas-based nucleic acid detection strategies and the application of CRISPR–Cas as a potential antiviral agent in the context of COVID-19.
format	article
author	Kok Gan Chan Geik Yong Ang Choo Yee Yu Chan Yean Yean
author_facet	Kok Gan Chan Geik Yong Ang Choo Yee Yu Chan Yean Yean
author_sort	Kok Gan Chan
title	Harnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics
title_short	Harnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics
title_full	Harnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics
title_fullStr	Harnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics
title_full_unstemmed	Harnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics
title_sort	harnessing crispr-cas to combat covid-19: from diagnostics to therapeutics
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/9da121a38a37495891d9221b3fdf9b83
work_keys_str_mv	AT kokganchan harnessingcrisprcastocombatcovid19fromdiagnosticstotherapeutics AT geikyongang harnessingcrisprcastocombatcovid19fromdiagnosticstotherapeutics AT chooyeeyu harnessingcrisprcastocombatcovid19fromdiagnosticstotherapeutics AT chanyeanyean harnessingcrisprcastocombatcovid19fromdiagnosticstotherapeutics
_version_	1718411512877416448

Harnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics

Ejemplares similares